Traws Pharma
TRAW
22 hedge funds and large institutions have $102M invested in Traws Pharma in 2013 Q3 according to their latest regulatory filings, with 22 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$24.3M |
| 2 |
WC
Weatherbie Capital
Boston,
Massachusetts
|
+$11.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.58M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$7.15M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$5.72M |
Top Sellers
TRAW Hedge Fund Activity: Q3 2013 in Review
22 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q3 2013, worth a combined $102M.
Buyers outnumbered sellers: 22 funds opened new TRAW positions and 0 closed out — a net gain of 22 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $24.3M.
- 22 institutional investors held Traws Pharma (TRAW) as of Q3 2013, up from 0 in Q2 2013.
- Funds reported $102M of Traws Pharma stock for Q3 2013.
- 22 funds opened new Traws Pharma positions in Q3 2013 and 0 closed out, a net change of +22 holders.
- The largest Traws Pharma buyer in Q3 2013 was Deerfield Management, an estimated $24.3M added.
Based on aggregated 13F filings for Q3 2013.